Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658210 | 0.86 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2AURKANTRK1 | |
| SCHEMBL5660027 | 0.86 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2AURKANTRK1 | |
| SCHEMBL1774779 | 0.84 | MAPT (0.45) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1773998 | 0.84 | MAPT (0.45) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1775484 | 0.84 | MAPT (0.42) | MAPTALDH1A1SMN1; SMN2NTRK1MEN1 | |
| SCHEMBL2174009 | 0.84 | ALDH1A1 (0.76) | MAPTALDH1A1SMN1; SMN2AURKAMEN1 | |
| SCHEMBL1773735 | 0.83 | LMNA (0.46) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1775201 | 0.83 | MEN1 (0.42) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1315419 | 0.83 | SYK (0.55) | MAPTALDH1A1SMN1; SMN2NTRK1MEN1 | |
| Fluoride SCHEMBL13518358 | 0.82 | SYK (0.54) | MAPTALDH1A1SMN1; SMN2NTRK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470812-B2 | Substituted benzo-pyrimido-tetrazolo-diazepine compounds | ARQULE, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470812-B2 | Substituted benzo-pyrimido-tetrazolo-diazepine compounds | ARQULE, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470812-B2 | Substituted benzo-pyrimido-tetrazolo-diazepine compounds | ARQULE, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20110166127-A1 | Substituted Benzo-Pyrimido-Tetrazolo-Diazepine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2011082269-A2 | SUBSTITUTED BENZO-PYRIMIDO-TETRAZOLO-DIAZEPINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110166127-A1 | Substituted Benzo-Pyrimido-Tetrazolo-Diazepine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166127-A1 | Substituted Benzo-Pyrimido-Tetrazolo-Diazepine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2011082269-A2 | SUBSTITUTED BENZO-PYRIMIDO-TETRAZOLO-DIAZEPINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166127-A1 | Substituted Benzo-Pyrimido-Tetrazolo-Diazepine Compounds | THPO, DHFR, BRD4 | MAPT 1923/4885ALDH1A1 1037/4885SMN1; SMN2 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.